Carisma Therapeutics, Inc. (CARM)

US — Healthcare Sector
Peers: JSPR  ONCO  ENVB  SPRC  SLXN  SLRX  REVB  CDT  INDP  ASBP 

Automate Your Wheel Strategy on CARM

With Tiblio's Option Bot, you can configure your own wheel strategy including CARM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CARM
  • Rev/Share 0.2577
  • Book/Share -1.1009
  • PB -0.0318
  • Debt/Equity -0.037
  • CurrentRatio 0.4799
  • ROIC 15.9775

 

  • MktCap 1462583.0
  • FreeCF/Share -0.8936
  • PFCF -0.0392
  • PE -0.0296
  • Debt/Assets 0.3392
  • DivYield 0
  • ROE 1.6229

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade CARM Robert W. Baird Outperform Neutral $10 $1 Dec. 12, 2024
Downgrade CARM BTIG Research Buy Neutral -- -- Dec. 10, 2024

News

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BASE and CARM on Behalf of Shareholders
BASE, CARM
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , June 23, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Couchbase, Inc. (NASDAQ: BASE)'s sale to Haveli Investments for $24.50 per share in cash. If you are a Couchbase shareholder, click here to learn more about your legal rights and options.

Read More
image for news SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BASE and CARM on Behalf of Shareholders

About Carisma Therapeutics, Inc. (CARM)

  • IPO Date 2014-02-06
  • Website https://carismatx.com
  • Industry Biotechnology
  • CEO Steven Kelly
  • Employees 46
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.